Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

High rates of chromosome missegregation suppress tumor progression but do not inhibit tumor initiation.

Zasadil LM, Britigan EM, Ryan SD, Kaur C, Guckenberger DJ, Beebe DJ, Moser AR, Weaver BA.

Mol Biol Cell. 2016 Jul 1;27(13):1981-9. doi: 10.1091/mbc.E15-10-0747. Epub 2016 May 4.

2.

Prevalence of ATM Sequence Variants in Northern Plains American Indian Cancer Patients.

Petereit DG, Hahn LJ, Kanekar S, Boylan A, Bentzen SM, Ritter M, Moser AR.

Front Oncol. 2013 Dec 30;3:318. doi: 10.3389/fonc.2013.00318. eCollection 2013.

3.

Apical pseudoaneurysm following continuous flow left ventricular assist device placement.

Moser AR, Hockman D, Magalski A, Main ML, Khumri TM, Austin BA.

Circ Heart Fail. 2012 May 1;5(3):e53-4. doi: 10.1161/CIRCHEARTFAILURE.111.966390. No abstract available.

PMID:
22589367
4.

Quantitative trait loci associated with susceptibility to bladder and kidney infections induced by Escherichia coli in female C3H/HeJ mice.

Hopkins WJ, Elkahwaji J, Kendziorski C, Moser AR, Briggs PM, Suhs KA.

J Infect Dis. 2009 Feb 1;199(3):355-61. doi: 10.1086/595987.

5.

Cytometric fingerprinting: quantitative characterization of multivariate distributions.

Rogers WT, Moser AR, Holyst HA, Bantly A, Mohler ER 3rd, Scangas G, Moore JS.

Cytometry A. 2008 May;73(5):430-41. doi: 10.1002/cyto.a.20545.

6.

Identification of novel modifier loci of Apc Min affecting mammary tumor development.

Wang H, Teske D, Tess A, Kohlhepp R, Choi Y, Kendziorski C, Moser AR.

Cancer Res. 2007 Dec 1;67(23):11226-33.

7.

Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis.

Ray R, Cabal-Manzano R, Moser AR, Waldman T, Zipper LM, Aigner A, Byers SW, Riegel AT, Wellstein A.

Cancer Res. 2003 Dec 1;63(23):8085-9.

8.

Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors.

Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, Cardiff RD.

Am J Pathol. 2002 Sep;161(3):1087-97.

9.

The ROSA26 LacZ-neo(R) insertion confers resistance to mammary tumors in Apc(Min/+) mice.

Kohlhepp RL, Hegge LF, Moser AR.

Mamm Genome. 2001 Aug;12(8):606-11.

PMID:
11471054
10.
11.

Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.

Karabinis ME, Larson D, Barlow C, Wynshaw-Boris A, Moser AR.

Carcinogenesis. 2001 Feb;22(2):343-6.

PMID:
11181458
12.

ROSA26 mice carry a modifier of Min-induced mammary and intestinal tumor development.

Kohlhepp RL, Hegge LF, Nett JE, Moser AR.

Mamm Genome. 2000 Dec;11(12):1058-62.

PMID:
11130972
13.

Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers.

Halberg RB, Katzung DS, Hoff PD, Moser AR, Cole CE, Lubet RA, Donehower LA, Jacoby RF, Dove WF.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3461-6.

14.

A resistant genetic background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity in ApcMin/+ mice.

Shoemaker AR, Moser AR, Midgley CA, Clipson L, Newton MA, Dove WF.

Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10826-31.

15.

Somatic mutational mechanisms involved in intestinal tumor formation in Min mice.

Shoemaker AR, Luongo C, Moser AR, Marton LJ, Dove WF.

Cancer Res. 1997 May 15;57(10):1999-2006.

16.

Studies of neoplasia in the Min mouse.

Shoemaker AR, Gould KA, Luongo C, Moser AR, Dove WF.

Biochim Biophys Acta. 1997 Apr 18;1332(2):F25-48. Review. No abstract available.

PMID:
9141462
17.

Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status.

Dove WF, Clipson L, Gould KA, Luongo C, Marshall DJ, Moser AR, Newton MA, Jacoby RF.

Cancer Res. 1997 Mar 1;57(5):812-4.

18.

Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice.

Gould KA, Luongo C, Moser AR, McNeley MK, Borenstein N, Shedlovsky A, Dove WF, Hong K, Dietrich WF, Lander ES.

Genetics. 1996 Dec;144(4):1777-85.

19.

Sulindac suppresses tumorigenesis in the Min mouse.

Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, Kinzler KW.

Carcinogenesis. 1996 Aug;17(8):1757-60.

PMID:
8761438
20.

Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam.

Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, Lubet RA, Kelloff GJ, Verma A, Moser AR, Dove WF.

Cancer Res. 1996 Feb 15;56(4):710-4.

22.

Homozygosity for the Min allele of Apc results in disruption of mouse development prior to gastrulation.

Moser AR, Shoemaker AR, Connelly CS, Clipson L, Gould KA, Luongo C, Dove WF, Siggers PH, Gardner RL.

Dev Dyn. 1995 Aug;203(4):422-33.

23.

ApcMin: a mouse model for intestinal and mammary tumorigenesis.

Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF.

Eur J Cancer. 1995 Jul-Aug;31A(7-8):1061-4. Review.

PMID:
7576992
24.

Emergent issues in the genetics of intestinal neoplasia.

Dove WF, Gould KA, Luongo C, Moser AR, Shoemaker AR.

Cancer Surv. 1995;25:335-55. Review.

PMID:
8718526
25.

Loss of Apc+ in intestinal adenomas from Min mice.

Luongo C, Moser AR, Gledhill S, Dove WF.

Cancer Res. 1994 Nov 15;54(22):5947-52.

26.

The adenomatous polyposis coli gene of the mouse in development and neoplasia.

Dove WF, Luongo C, Connelly CS, Gould KA, Shoemaker AR, Moser AR, Gardner RL.

Cold Spring Harb Symp Quant Biol. 1994;59:501-8. Review. No abstract available.

PMID:
7587105
27.

Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse.

Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove W.

Cell. 1993 Nov 19;75(4):631-9.

PMID:
8242739
28.

Transgenic mouse models that explore the multistep hypothesis of intestinal neoplasia.

Kim SH, Roth KA, Moser AR, Gordon JI.

J Cell Biol. 1993 Nov;123(4):877-93.

29.

ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias.

Moser AR, Mattes EM, Dove WF, Lindstrom MJ, Haag JD, Gould MN.

Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8977-81.

30.

Mapping of multiple intestinal neoplasia (Min) to proximal chromosome 18 of the mouse.

Luongo C, Gould KA, Su LK, Kinzler KW, Vogelstein B, Dietrich W, Lander ES, Moser AR.

Genomics. 1993 Jan;15(1):3-8.

PMID:
8094372
31.

Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.

Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF.

Science. 1992 May 1;256(5057):668-70. Erratum in: Science 1992 May 22;256(5060):1114.

PMID:
1350108
33.

A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse.

Moser AR, Pitot HC, Dove WF.

Science. 1990 Jan 19;247(4940):322-4.

PMID:
2296722
34.

Mapping to molecular resolution in the T to H-2 region of the mouse genome with a nested set of meiotic recombinants.

King TR, Dove WF, Herrmann B, Moser AR, Shedlovsky A.

Proc Natl Acad Sci U S A. 1989 Jan;86(1):222-6.

35.

H-2 class I and Gt (H-2) antigens are identical: evidence from H-2 mutant mice.

Moser AR, Shedlovsky A, Johnson LL.

Immunogenetics. 1986;23(4):271-3. No abstract available.

PMID:
2422118
36.

Supplemental Content

Loading ...
Support Center